MIGS Consulting, LLC — research payments reported

By program year

6 rows

Year	Kind	Amount	Payments
2025	Research	$187,153	29
2024	Research	$174,317	26
2023	Research	$137,963	25
2022	Research	$269,868	24
2021	Research	$139,290	13
2020	Research	$41,110	7

Breakdown

Who paid Research payments · program years 2020–2025

Glaukos Corporation $898,884 121 payments
Ocular Therapeutix, Inc. $50,817 3 payments

Studies the money was for Research payments · program years 2020–2025

Multicenter, Randomized, Double-masked Trial to Evaluate the Safety and Efficacy of iDose TR (travoprost intraocular implant) in Conjunction with the Placement of iStent infinite vs. iStent infinite Alone in Subjects with Open-angle Glaucoma or Ocular Hypertension $200,262 22 payments
iStent Inject Trabecular Micro-Bypass System New Enrollment Post-Approval Study $163,285 13 payments
A Prospective, Multicenter Study of the Glaukos Istent Infinite Trabecular Micro-Bypass System Model Is3 in Subjects With Mild to Moderate Primary Open-Angle Glaucoma $98,145 9 payments
Prospective, Randomized Phase 3 Study Comparing Two Models of a Travoprost Intraocular Implant to Timolol Maleate Ophthalmic Solution, USP, 0.5% $64,312 12 payments
iStent Inject Trabecular Micro-Bypass System New Enrollment Post-Approval Study $53,660 18 payments
iStent Inject Trabecular Micro-Bypass System New Enrollment Post-Approval Study $48,020 12 payments
A prospective, multi-center, randomized, parallel-group, controlled study to evaluate the efficacy and safety of OTX-TIC (travoprost) intracameral implant in subjects with open-angle glaucoma (OAG) or ocular hypertension (OHT) $26,131 2 payments
A prospective, multi-center, randomized, parallel-group, controlled study to evaluate the efficacy and safety of OTX-TIC (travoprost) intracameral implant in subjects with open-angle glaucoma (OAG) or ocular hypertension (OHT) $24,686 1 payment
iStent Inject Trabecular Micro-Bypass System Continuation Post-Approval Study $17,115 7 payments
Prospective, Randomized Phase 3 Study Comparing Two Models of a Travoprost Intraocular Implant to Timolol Maleate Ophthalmic Solution, USP, 0.5% $8,703 4 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.